ArticleJournal of virology2010
Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle.Veterinary immunology and immunopathology · 2016Trial
- Review
- STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity.Molecular biology reports · 2024Review
- Defining correlates of protection for mammalian livestock vaccines against high-priority viral diseases.Frontiers in immunology · 2024Review
- Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle.Frontiers in microbiology · 2024Article
- Preventive effects of quercetin against foot-and-mouth disease virusFrontiers in microbiology · 2023Article
- Treatment with Ad5-Porcine Interferon-α Attenuates Ebolavirus Disease in Pigs.Pathogens (Basel, Switzerland) · 2022Article
- PorvacVaccines · 2021Article
- Use of Protein Pegylation to Prolong the Antiviral Effect of IFN Against FMDV.Frontiers in microbiology · 2021Article
- A Wide-Ranging Antiviral Response in Wild Boar Cells Is Triggered by Non-coding Synthetic RNAs From the Foot-and-Mouth Disease Virus Genome.Frontiers in veterinary science · 2020Article
- Use of IFN-Based Biotherapeutics to Harness the Host Against Foot-And-Mouth Disease.Frontiers in veterinary science · 2020Review
- Interferon as a Mucosal Adjuvant for an Influenza Vaccine in Pigs.Virologica Sinica · 2019Article
- The Different Tactics of Foot-and-Mouth Disease Virus to Evade Innate Immunity.Frontiers in microbiology · 2018Review
- Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response.Frontiers in cellular and infection microbiology · 2017Review
- Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease.Journal of virology · 2016Article
- The Pathogenesis of Foot-and-Mouth Disease in Pigs.Frontiers in veterinary science · 2016Review
- Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2016Article
- Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.Clinical and vaccine immunology : CVI · 2015Article
- Multifunctional roles of leader protein of foot-and-mouth disease viruses in suppressing host antiviral responses.Veterinary research · 2015Review
- Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs.Journal of virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we demonstrated that type I interferon (IFN-alpha/beta) or a combination of IFN-alpha/beta and type II IFN (IFN-gamma) delivered by a replication-defective human adenovirus 5 (Ad5) vector protected swine when challenged 1 day later with foot-and-mouth disease virus (FMDV). To gain a more comprehensive understanding of the mechanism of protection induced by IFNs, we inoculated groups of six swine with Ad5-vectors containing these genes, challenged 1 day later and euthanized 2 animals from each group prior to (1 day postinoculation [dpi]) and at 1 (2 dpi) and 6 days postchallenge (7 dpi). Blood, skin, and lymphoid tissues were examined for IFN-stimulated gene (ISG) induction and infiltration by innate immune cells. All IFN-inoculated animals had delayed and decreased clinical signs and viremia compared to the controls, and one animal in the IFN-alpha treated group did not develop disease. At 1 and 2 dpi the groups inoculated with the IFNs had increased numbers of dendritic cells and natural killer cells in the skin and lymph nodes, respectively, as well as increased levels of several ISGs compared to the controls. In particular, all tissues examined from IFN-treated groups had significant upregulation of the chemokine 10-kDa IFN-gamma-inducible protein 10, and preferential upregulation of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-dioxygenase. There was also upregulation of monocyte chemotactic protein 1 and macrophage inflammatory protein 3alpha in the skin. These data suggest that there is a complex interplay between IFN-induced immunomodulatory and antiviral activities in protection of swine against FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.